Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target boosted by JPMorgan Chase & Co. from $33.00 to $38.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts also recently issued reports on SNDX. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 15th. Stifel Nicolaus boosted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. Barclays boosted their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. HC Wainwright boosted their target price on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. Finally, Bank of America boosted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Stock Up 3.1 %

NASDAQ:SNDX opened at $16.09 on Thursday. Syndax Pharmaceuticals has a 52 week low of $15.00 and a 52 week high of $25.34. The company has a market capitalization of $1.37 billion, a P/E ratio of -4.43 and a beta of 0.92. The stock’s fifty day moving average is $18.60 and its two-hundred day moving average is $20.00.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the prior year, the firm posted ($0.73) EPS. Sell-side analysts anticipate that Syndax Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SNDX. Iron Triangle Partners LP acquired a new position in shares of Syndax Pharmaceuticals during the 1st quarter worth about $23,159,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $15,165,000. Eventide Asset Management LLC purchased a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at about $15,150,000. First Turn Management LLC purchased a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $13,147,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after purchasing an additional 591,631 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).